Wolters Kluwer | Medi-Span | Drug Data Unity

The future of drug data unity: realistic or idealistic?

Envision a future where drug data unity saves lives.

News & Press Release

If we continue down the path of automation and AI, our workforce is bound to undergo creative transformations

Date Announced

Share Buyback Program

Status

February 24, 2021 and subsequently expanded

Up to €410 million, in 2021, including amounts to offset dilution from incentive share issuance.

In progress

For a weekly update, see Share Buyback Transactions

February 26, 2020

Up to €350 million, in 2020, including amounts to offset dilution from incentive share issuance.

Completed December 29, 2020: 5.1 million shares repurchased for €350 million (average price €68.41)

Section Headline

Description Text

Some quick example text to build on the card title and make up the bulk of the card's content.

Description Text

Some quick example text to build on the card title and make up the bulk of the card's content.

Description Text

Some quick example text to build on the card title and make up the bulk of the card's content.

Watch Video

On the front line of knowledge

Built by a team of nursing educators and experts in health informatics, Lippincott DocuCare teaches students the fundamentals of effective electronic documentation while fostering clinical judgment and critical thinking.

Is drug data unity possible? We have thoughts.

Inconsistent and incompatible drug and patient data streams result in business inefficiencies and, more importantly, harmful variances in care throughout medical institutions globally. We envision a better future, where the healthcare industry can improve data quality and sharing to improve care.

In the white paper below, Wolters Kluwer experts explore the key considerations in addressing gaps in drug data unity:

The practical vs. the impractical: Is a fully interoperable data exchange between healthcare organizations possible?
Improving how and what we share: Will we conform to standards and quality checks — and be willing to share data?

The future of drug data unity, and fewer medication-related care errors, can start today.

Download now

Read the white paper to learn how to be part of the solution.

Product Interest CDI:

utm_campaign:

utm_content:

utm_medium:

utm_source:

utm_term:

What solutions are you interested in?

Which of the following challenges is your organization looking to address?

What is your role in purchasing clinical decision support?

Does your organization have funds for Health IT Investments?

Are you considering enhancing your clinical decision support capabilities?

Expert Insights

Stay informed

Subscribe to CT Corporation's newsletters for business compliance updates and legislative news.

The EmmiTransition platform helps care teams optimize their time...

Our leadership in AI technology helps you more quickly and accurately identify patients at risk. That’s just one example of our dedication to understanding your challenges and priorities and applying our culture of innovation to meet your needs.

The future of drug data unity, and fewer medication-related care errors, can start today.

Read the white paper to learn how to be part of the solution.